XNCRHealthcare · BiotechnologyThe 14 Wall Street analysts covering Xencor, Inc. hold a median 12-month price target of $30 — +22.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 8 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Xencor, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (94): The shares have been drifting up relative to others.
Growth (34): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on XNCR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +22.4% from it.
Of the 20 most recent actions, 8 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Sept 2026 | Truist Securities | Reiterates | Buy | $27 → $29 |
| 21 Sept 2026 | B of A Securities | Maintains | Neutral | $20 → $26 |
| 11 Sept 2026 | Barclays | Maintains | Overweight | $27 → $35 |
| 11 Sept 2026 | Barclays | Maintains | Overweight | — |
| 3 Sept 2026 | JP Morgan | Maintains | Neutral | — |
| 3 Sept 2026 | JP Morgan | Maintains | Neutral | $14 → $21 |
| 1 Sept 2026 | Raymond James | Maintains | Strong Buy | — |
| 1 Sept 2026 | Raymond James | Maintains | Strong Buy | $40 → $46 |
| 6 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | $43 → $44 |
| 6 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 6 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 6 Aug 2026 | RBC Capital | Maintains | Outperform | $19 → $20 |
| 6 Aug 2026 | Wedbush | Maintains | Outperform | $26 → $30 |
| 6 Aug 2026 | Wedbush | Maintains | Outperform | — |
| 30 July 2026 | Wedbush | Reiterates | Outperform | $26 |
| 30 July 2026 | Wedbush | Reiterates | Outperform | — |
| 7 July 2026 | Truist Securities | Maintains | Buy | — |
| 7 July 2026 | Truist Securities | Maintains | Buy | $29 → $27 |
| 11 May 2026 | JP Morgan | Maintains | Neutral | — |
| 24 Mar 2026 | JP Morgan | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XNCR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Xencor, Inc. returned +97.6% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 96% of US stocks
Cheaper than 10% of US stocks
Cheaper than 28% of US stocks
Cheaper than 82% of US stocks
Higher than 66% of US stocks
Higher than 56% of US stocks
Higher than 15% of US stocks
Higher than 4% of US stocks
Higher than 27% of US stocks
Higher than 21% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Xencor, Inc. has a market value of $1.8B and an enterprise value of $1.5B.
Revenue in the twelve months to 30 June 2026: $105.0M. The latest quarter grew 17.5% year on year.
Net income over the same four quarters: −$163.3M, a −155.6% net margin.
Diluted earnings per share, trailing twelve months: $−2.17.
Free cash flow in the twelve months to 30 June 2026: −$208.3M.
Trailing P/E: −18.4×; forward P/E: −6.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Xencor, Inc. employs 260 people — $404K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Xencor, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Xencor’s settlement with Alexion improved its financial runway, which the excerpt says should extend through obexelimab’s FDA PDUFA decision for IgG4-related disease. Obexelimab is partnered, so Xencor would receive royalties and milestones.
Why it matters — The improved runway and potential partnered-asset payments are relevant to Xencor’s funding outlook and pipeline progress.
Xencor, Inc. announced that company management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m. EDT. A live webcast of the presentation will be available in the Investors section of Xencor's website.
Why it matters — The presentation gives XNCR watchers an opportunity to hear directly from company management about its clinical-stage antibody programs for cancer and autoimmune diseases.
Xencor reported a second-quarter loss of $0.29 per share, which was narrower than the Zacks Consensus Estimate of a loss of $0.82 and the $0.41 per-share loss reported a year ago. The results beat revenue estimates.
Why it matters — A narrower-than-expected quarterly loss and revenue beat could signal improving financial performance for Xencor investors tracking the company's results.
Xencor reported its financial results for the second quarter ended June 30, 2026. President and CEO Bassil Dahiyat said the company is excited to present XmAb819 results at ESMO this fall along with other fast-approaching milestones across its wholly owned clinical pipeline.
Why it matters — The news highlights upcoming clinical data and pipeline milestones for Xencor's wholly owned programs, which are relevant events for XNCR shareholders to watch.
Xencor announced a Settlement Agreement with Alexion to resolve a commercial dispute related to U.S. royalties on Ultomoris (ravulizumab-cwvz). Under the agreement, Xencor will receive a payment from Alexion.
Why it matters — The resolution of this royalty dispute and the resulting payment provide clarity on a financial overhang for Xencor.
The 14 Wall Street analysts covering Xencor, Inc. have a median 12-month price target of $30, with estimates ranging from $20 to $46. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Xencor, Inc., 12 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xencor, Inc. 83 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Xencor, Inc. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +22.4% from the last close, and Ticker Nerd's factor model ranks Xencor, Inc. 83 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Xencor, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XNCR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $46 over the next 12 months.
Xencor, Inc. returned +97.6% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Xencor Inc. is a clinical-stage biopharmaceutical company focused on designing and developing engineered antibody therapeutics for cancer, autoimmune disorders, and other serious diseases.
The most recent item we track (Seeking Alpha, 7 Oct 2026): "Xencor: Better Funding For Obexelimab". Xencor’s settlement with Alexion improved its financial runway, which the excerpt says should extend through obexelimab’s FDA PDUFA decision for IgG4-related disease. Obexelimab is partnered, so Xencor would receive royalties and milestones.
Xencor Inc. is a clinical-stage biopharmaceutical company focused on designing and developing engineered antibody therapeutics for cancer, autoimmune disorders, and other serious diseases. The company’s XmAb protein engineering platform is used to create next-generation antibodies and bispecific molecules with tailored biological activity, supporting a portfolio of proprietary and partnered programs in clinical development. Xencor’s work centers on protein engineering that can improve how therapies interact with immune targets and disease pathways, making it a specialized participant in modern antibody drug innovation. The company also collaborates with external partners to apply its platform across multiple therapeutic areas, including oncology and immunology. Headquartered in Pasadena, California, Xencor Inc. operates as a biotechnology company whose current business is built around research, development, and collaboration in advanced biologic medicines.
CEO Dr. Bassil I. Dahiyat Ph.D. · 260 employees · United States · https://www.xencor.com
